Download Files:

Pevonedistat

SKU HY-70062-1 mg Category Reference compound Tags Cancer, Metabolic Enzyme/Protease, NEDD8-activating Enzyme

$60 – $1,680

Size

1 mg 5 mg 10mM/1mL 10 mg 50 mg 100 mg 200 mg

Clear

Products Details

Product Description

– Pevonedistat (MLN4924) is a potent and selective NEDD8-activating enzyme (NAE) inhibitor with an IC50 of 4.7 nM[1].

Web ID

– HY-70062

Storage Temperature

– -20°C, 3 years; 4°C, 2 years (Powder)

Shipping

– Room Temperature

Applications

– Cancer-programmed cell death

Molecular Formula

– C21H25N5O4S

Citations

– Am J Physiol Lung Cell Mol Physiol. 2017 Jul 1;313(1):L104-L114.|Am J Physiol Lung Cell Mol Physiol. 2019 Jun 1;316(6):L1070-L1080. |Ann Hematol. 2014 Sep;93(9):1499-508.|Arch Biochem Biophys. 2021 Jul 31;109000.|Arch Biochem Biophys. 2022 May 30;721:109194.|Biochem Biophys Res Commun. 2017 Jan 29;483(1):223-229. |Biochem Biophys Res Commun. 2018 Nov 17;506(1):108-113. |Biochem Biophys Res Commun. 2019 Sep 3;516(4):1242-1247. |Biochem Biophys Res Commun. 2021 Mar 3;549:150-156.|Biochem Biophys Res Commun. 2019 Jan 15;508(3):986-990. |bioRxiv. 2023 Feb 15.|bioRxiv. 2023 Feb 23.|bioRxiv. 2023 Jun 5.|bioRxiv. April.|Biosci Rep. 2022 Jul 26;BSR20220994.|Cancer Cell. 2020 Mar 16;37(3):371-386.e12.|Cancer Chemother Pharmacol. 2018 Jun;81(6):1083-1093.|Cancers. 2019 Jan 15;11(1):97.|Cell Biosci. 2020 Nov 27;10(1):139.|Cell Chem Biol. 2021 Jul 15;S2451-9456(21)00312-3.|Cell Cycle. 2019 Sep;18(18):2307-2322.|Cell Death Differ. 2020 Apr;27(4):1383-1397. |Cell Death Differ. 2021 Jul 2.|Cell Death Discov. 2022 Jul 12;8(1):316.|Cell Death Discov. 2022 May 2;8(1):238.|Cell Metab. 2023 Jul 28;S1550-4131(23)00263-2.|Cell Rep. 2021 Aug 24;36(8):109568.|Cell Rep. 2021 Jul 20;36(3):109394.|Cell Res. 2021 Mar;31(3):291-311.|Cell. 2019 Jul 11;178(2):330-345.e22.|Cell. 2023 Apr 27;186(9):1895-1911.e21.|Cells. 2020 Mar 30;9(4):834.|Cells. 2021, 10(11), 2803.|Clin Transl Med. 2020 Jun;10(2):e113.|Commun Biol. 2021 Sep 13;4(1):1066.|Comput Struct Biotechnol J. 1 October 2021.|Dev Cell. 2019 Feb 11;48(3):329-344.e5.|Elife. 2016 Apr 11;5:e14087.|Elife. 2018 Aug 1;7:e38430. |Elife. 2020 Jun 2;9:e54954.|Elife. 2019 Mar 25;8:e45457. |EMBO J. 2019 Dec 2;38(23):e101409.|Eur J Med Chem. 2023 Aug 19, 115732.|Eur Rev Med Pharmacol Sci. 2018 Dec;22(23):8273-8280.|Exp Cell Res. 2020 Jul 15;392(2):112038.|FASEB J. 2021 Aug;35(8):e21800.|Front Cell Dev Biol. 2021 Apr 30.|Front Cell Dev Biol. 2021 Apr 30;9:667435.|Front Immunol. 2022 Jul 4;13:925702.|Front Oncol. 2017 Dec 11;7:293.|Front Oncol. 2022 Jan 26;12:822039.|Institut für Pharmazeutische Wissenschaften. 2020 Nov.|Institute of Molecular Virology. Ulm University. 2017 Jan.|Int J Med Sci. 2018 Apr 3;15(7):674-681.|Int J Mol Sci. 2023, 24(4), 3415.|iScience. 2023 Mar.|J Biol Chem. 15 October 2021, 101307.|J Biol Chem. 2022 Sep 12;102484.|J Cell Physiol. 2022 May 16.|J Exp Med. 2018 Aug 6;215(8):1999-2017. |J Immunol. 2021 Jun 28;ji2001167.|J Med Chem. 2021 Dec 29.|J Med Chem. 2021 Jun 17.|J Med Chem. 2023 Jun 30.|J Med Chem. 2023 Mar 9.|J Med Chem. 2023 Sep 6.|J Virol. 2022 May 25;96(10):e0059822.|Lab Invest. 2019 Apr;99(4):528-538.|Mbio. 2020 Jul 14;11(4):e00782-20.|Mol Cancer Res. 2023 Feb 8;MCR-22-0648.|Mol Cell. 2022 Feb 17;S1097-2765(22)00085-5.|Mol Cell. 2023 Nov 16:S1097-2765(23)00913-9.|Mol Metab. 2021 Jun 18;101275.|Mol Ther Oncolytics. 2020 Jun 23;18:215-225.|Nat Chem Biol. 2023 Aug 31.|Nat Chem Biol. 2023 Sep 7.|Nat Commun. 2017 May 22;8:15398. |Nat Commun. 2018 Sep 18;9(1):3801. |Nat Commun. 2021 Sep 10;12(1):5386.|Nat Commun. 2022 Oct 10;13(1):5973.|Nat Commun. 2022 Sep 2;13(1):5173.|Nat Microbiol. 2019 May;4(5):813-825.|Nat Plants. 2019 Jan;5(1):34-40. |Nature Cancer. 2021 Apr;2(4):429-443.|Nature. 2020 Dec;588(7836):164-168.|Neoplasia. 2022 Jul 27;32:100823.|Neurobiol Dis. 2020 Sep;143:105013.|Oncol Lett. 2019 Sep;18(3):2724-2732. |Oncotarget. 2016 Jun 14;7(24):35643-35654.|Oncotarget. 2016 Oct 4;7(40):66087-66099.|Oncotarget. 2017 Sep 23;8(49):86395-86409. |Patent. US20180263995A1.|Patent. US20220175722A1.|Patent. US20220280649A1.|Patent. US20220281931A1.|Patent. US20220378919A1.|Proc Natl Acad Sci U S A. 2022 Feb 8;119(6):e2111737119.|Protein Sci. 2021 Aug 30.|Redox Biol. 2021 Aug 24;46:102114.|Research Square Preprint. 2021 Jun.|Research Square Preprint. 2022 Jul.|Research Square Print. 2022.|Technol Cancer Res Treat. 2016 Aug;15(4):527-34. |Virology. 2015 Mar;477:10-7. |Viruses. 2023 Nov 30, 15(12), 2356.|Harvard Medical School LINCS LIBRARY|J Pathol. 2021 Feb 27.|Oncotarget. 2017 Oct 12;8(57):97178-97186. |Sci Adv. 2022 Sep 23;8(38):eabq4831.

References

– [1]F S Wolenski, et al. The NAE inhibitor pevonedistat (MLN4924) synergizes with TNF-α to activate apoptosis. Cell Death Discovery 1, Article number: 15034 (2015)|[2]Soucy TA, et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature. 2009 Apr 9;458(7239):732-6.

CAS Number

– 905579-51-3

Molecular Weight

– 443.52

Compound Purity

– 99.98

SMILES

– O=S(OC[C@@H]1C[C@@H](N2C3=NC=NC(N[C@H]4CCC5=C4C=CC=C5)=C3C=C2)C[C@@H]1O)(N)=O

Clinical Information

– Phase 3

Research Area

– Cancer

Solubility

– DMSO : 62.5 mg/mL (ultrasonic)

Target

– NEDD8-activating Enzyme

Pathway

– Metabolic Enzyme/Protease

Product type

– Reference compound

Booklet

Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.